Financial news sources report that the Hong Kong stock exchange listing application for Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ), filed on February 12, 2026, has officially expired after six months on August 12, 2026. At the time of submission, Goldman Sachs, Citigroup, and CITIC Securities acted as the joint sponsors for the listing.

According to the previous prospectus, Shenzhen Salubris is a pioneering company in China's cardiovascular-kidney-metabolic (cardiometabolic syndrome) disease treatment field. Based on data from Frost & Sullivan, the company was the second-largest pharmaceutical enterprise in China's cardiovascular innovative drug market by revenue in 2024. As of the latest practicable date (February 4, 2026), the company held the second-largest pipeline of cardiometabolic syndrome innovative drugs among domestic firms, according to the same source.

The company's product portfolio is strategically centered on innovative drugs, while also encompassing generics, biosimilars, and medical devices. These offerings work synergistically to address the significant unmet medical needs in the cardiometabolic syndrome area. Shenzhen Salubris has consistently led innovation in this field. As of the latest practicable date, the company has six innovative drugs: Salubritan (approved in 2013), Fulitan (approved in 2024), Salubritin (approved in 2024), Xinchao Tuo (approved in 2025), Fulian (approved in 2025), and Ennalo (initially approved in 2023, with expanded indications approved in 2025).

The market share of these drugs is rapidly increasing, and they are expected to become a key driver of the company's revenue growth. The proportion of innovative drug sales revenue to total pharmaceutical sales revenue rose from 30.1% in 2023 to 37.7% in 2024, and surged from 35.5% in the nine months ended September 30, 2024, to 51.6% in the same period of 2025.